Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Eye (London, England)|February 9, 2025
Safety and efficacy of a novel 'One-Visit, Both-Cataracts' high-volume see-and-treat immediate sequential bilateral cataract surgery service in a public healthcare settingMaher Alsusa, Shakeel Ahmad, Zoe Smith, et al.
Family Practice|January 22, 2022
A cross-sectional study of the practice types of US adult primary care physician specialistsRichard A Young, Elizabeth Wilkinson, Tyler W Barreto, et al.
Journal of Graduate Medical Education|January 4, 2021
Rural Workforce Years: Quantifying the Rural Workforce Contribution of Family Medicine Residency GraduatesPeter Meyers, Elizabeth Wilkinson, Stephen Petterson, et al.
Frontiers in Pediatrics|January 30, 2025
Pedals possible: a pilot study of adaptive cycling as a school-based rehabilitation intervention for students with disabilitiesJulia S Brennan, Everette Keller, Elizabeth Humanitzki, et al.
Journal of Medical Screening|January 9, 2023
Test accuracy of artificial intelligence-based grading of fundus images in diabetic retinopathy screening: A systematic reviewZhivko Zhelev, Jaime Peters, Morwenna Rogers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancerStephen R D Johnston, Tamas Hickish, Paul Ellis, et al.
Aviation, Space, and Environmental Medicine|July 12, 2012
Pulmonary artery pressure increases during commercial air travel in healthy passengersThomas G Smith, Nick P Talbot, Rae W Chang, et al.
Population Health Management|July 16, 2020
The Role of the Private Sector in Advancing Antimicrobial Stewardship: Recommendations from the Global Chief Medical Officers' NetworkElizabeth D Hermsen, Richard Jenkins, Ivo Vlaev, et al.
Breast Cancer Research and Treatment|March 16, 2012
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabNancy U Lin, Eric P Winer, Duncan Wheatley, et al.
The Lancet. Oncology|May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Pageof 4